Hera Therapeutics Inc., a biotech startup operating in the Janssen Labs incubator, has raised $1.7 million in equity financing from 19 investors, according to a Dec. 23 filing with the U.S. Securities and Exchange Commission.

The filing indicates the company is seeking to sell an additional $800,000 in equity as part of the current financing, which comes about five months after the company raised a little more than $1.1 million from 14 investors in a separate equity financing.

Hera Therapeutics, founded in 2012 and with offices in Del Mar, is focused on developing and commercializing direct-acting antivirals for infections with the human papilloma virus, human and animal retroviruses, and herpes group viruses, according to a description on Janssen Labs’ website.

The company’s CEO is Karl Hostetler.